Rice Hall James & Associates LLC Sells 8,263 Shares of Lantheus Holdings Inc (NASDAQ:LNTH)

Rice Hall James & Associates LLC lowered its position in Lantheus Holdings Inc (NASDAQ:LNTH) by 7.5% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 101,510 shares of the medical equipment provider’s stock after selling 8,263 shares during the period. Rice Hall James & Associates LLC owned about 0.26% of Lantheus worth $2,873,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. TD Asset Management Inc. raised its position in Lantheus by 1.4% in the 2nd quarter. TD Asset Management Inc. now owns 63,009 shares of the medical equipment provider’s stock worth $1,783,000 after purchasing an additional 900 shares during the period. Hussman Strategic Advisors Inc. purchased a new position in shares of Lantheus during the second quarter worth approximately $2,830,000. Aperio Group LLC purchased a new position in shares of Lantheus during the second quarter worth approximately $109,000. KBC Group NV purchased a new position in shares of Lantheus during the second quarter worth approximately $476,000. Finally, Dupont Capital Management Corp increased its position in shares of Lantheus by 194.2% during the second quarter. Dupont Capital Management Corp now owns 45,341 shares of the medical equipment provider’s stock worth $1,283,000 after acquiring an additional 29,931 shares during the period. 91.35% of the stock is owned by institutional investors.

Shares of NASDAQ:LNTH traded down $0.32 during trading on Thursday, reaching $20.98. 2,584 shares of the company were exchanged, compared to its average volume of 491,893. The company has a market capitalization of $863.75 million, a price-to-earnings ratio of 22.19, a PEG ratio of 1.76 and a beta of 1.47. The business’s fifty day simple moving average is $25.84. Lantheus Holdings Inc has a 12-month low of $12.59 and a 12-month high of $29.80. The company has a quick ratio of 2.01, a current ratio of 2.62 and a debt-to-equity ratio of 2.05.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, July 25th. The medical equipment provider reported $0.27 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.27. The business had revenue of $85.70 million for the quarter, compared to analyst estimates of $88.72 million. Lantheus had a net margin of 11.20% and a return on equity of 51.08%. The company’s quarterly revenue was up .1% compared to the same quarter last year. During the same period last year, the company posted $0.25 earnings per share. On average, sell-side analysts expect that Lantheus Holdings Inc will post 1.06 EPS for the current fiscal year.

In other news, SVP Michael P. Duffy sold 8,819 shares of the stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $28.14, for a total transaction of $248,166.66. Following the transaction, the senior vice president now directly owns 144,494 shares in the company, valued at $4,066,061.16. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Derace L. Schaffer sold 20,000 shares of the stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $23.82, for a total transaction of $476,400.00. Following the transaction, the director now owns 36,994 shares in the company, valued at $881,197.08. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 136,187 shares of company stock worth $3,604,063. Corporate insiders own 2.60% of the company’s stock.

A number of equities analysts have recently commented on the stock. ValuEngine lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. BidaskClub lowered shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 11th. Finally, Zacks Investment Research lowered shares of Lantheus from a “hold” rating to a “sell” rating in a research report on Friday, August 2nd.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Further Reading: What is the price-to-earnings growth (PEG) ratio?

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings Inc (NASDAQ:LNTH).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.